Spots Global Cancer Trial Database for recurrent waldenstrom macroglobulinemia

Every month we try and update this database with for recurrent waldenstrom macroglobulinemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma	NCT01381692	Recurrent Folli... Recurrent Mantl... Recurrent Margi... Recurrent Non-H... Recurrent Small... Recurrent Walde... Refractory Foll... Refractory Mant... Refractory Marg... Refractory Non-... Refractory Smal...	Bortezomib Dexamethasone Laboratory Biom... Quality-of-Life... Rituximab Temsirolimus	18 Years -	National Cancer Institute (NCI)
Pomalidomide in Treating Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia	NCT01198067	Recurrent Walde... Refractory Wald...	Pomalidomide	18 Years -	M.D. Anderson Cancer Center
Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma	NCT04635683	Recurrent B-Cel... Recurrent Extra... Recurrent Folli... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Recurrent Nodal... Recurrent Splen... Recurrent Walde... Refractory B-Ce... Refractory Extr... Refractory Foll... Refractory Grad... Refractory Grad... Refractory Grad... Refractory Lymp... Refractory Mant... Refractory Marg... Refractory Noda... Refractory Sple... Refractory Wald...	Lenalidomide Ublituximab Umbralisib	18 Years -	Ohio State University Comprehensive Cancer Center
Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas	NCT02332980	Recurrent B-Cel... Recurrent Chron... Recurrent Extra... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Lymph... Recurrent Margi... Recurrent Nodal... Recurrent Small... Recurrent Splen... Recurrent Walde... Refractory B-Ce... Refractory Chro... Refractory Extr... Refractory Foll... Refractory Lymp... Refractory Noda... Refractory Smal... Refractory Sple... Refractory Wald... Richter Syndrom... Waldenstrom Mac...	Ibrutinib Idelalisib Laboratory Biom... Pembrolizumab	18 Years -	Mayo Clinic
Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma	NCT04635683	Recurrent B-Cel... Recurrent Extra... Recurrent Folli... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Recurrent Nodal... Recurrent Splen... Recurrent Walde... Refractory B-Ce... Refractory Extr... Refractory Foll... Refractory Grad... Refractory Grad... Refractory Grad... Refractory Lymp... Refractory Mant... Refractory Marg... Refractory Noda... Refractory Sple... Refractory Wald...	Lenalidomide Ublituximab Umbralisib	18 Years -	Ohio State University Comprehensive Cancer Center
Pomalidomide in Treating Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia	NCT01198067	Recurrent Walde... Refractory Wald...	Pomalidomide	18 Years -	M.D. Anderson Cancer Center
Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma	NCT01381692	Recurrent Folli... Recurrent Mantl... Recurrent Margi... Recurrent Non-H... Recurrent Small... Recurrent Walde... Refractory Foll... Refractory Mant... Refractory Marg... Refractory Non-... Refractory Smal...	Bortezomib Dexamethasone Laboratory Biom... Quality-of-Life... Rituximab Temsirolimus	18 Years -	National Cancer Institute (NCI)
Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia	NCT03506373	Recurrent Walde... Refractory Wald... Waldenstrom Mac...	Ibrutinib Ixazomib Citrat... Laboratory Biom... Pharmacodynamic... Pharmacokinetic...	18 Years -	Mayo Clinic
Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma	NCT03147885	Diffuse Large B... Recurrent B-Cel... Recurrent Extra... Recurrent Folli... Recurrent Indol... Recurrent Mantl... Recurrent Margi... Recurrent Walde... Refractory B-Ce... Refractory Extr... Refractory Foll... Refractory Mant... Stage III Non-H... Stage IV Non-Ho... Transformed Rec...	Selinexor	18 Years -	Barbara Ann Karmanos Cancer Institute
Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas	NCT02332980	Recurrent B-Cel... Recurrent Chron... Recurrent Extra... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Lymph... Recurrent Margi... Recurrent Nodal... Recurrent Small... Recurrent Splen... Recurrent Walde... Refractory B-Ce... Refractory Chro... Refractory Extr... Refractory Foll... Refractory Lymp... Refractory Noda... Refractory Smal... Refractory Sple... Refractory Wald... Richter Syndrom... Waldenstrom Mac...	Ibrutinib Idelalisib Laboratory Biom... Pembrolizumab	18 Years -	Mayo Clinic
Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma	NCT02950220	B-Cell Lymphoma... Grade 1 Follicu... Grade 2 Follicu... Grade 3a Follic... Mediastinal Lym... Recurrent B-Cel... Recurrent Burki... Recurrent Diffu... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Recurrent Walde... Refractory B-Ce... Refractory Burk... Refractory Diff... Refractory Foll... Refractory Lymp... Refractory Mant...	Ibrutinib Laboratory Biom... Pembrolizumab	18 Years -	Ohio State University Comprehensive Cancer Center

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: